Arrowhead Common Stock Shares Outstanding vs Total Liab Analysis
ARWR Stock | USD 26.50 0.66 2.55% |
Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Common Stock Shares Outstanding and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.
Common Stock Shares Outstanding vs Total Liab
Common Stock Shares Outstanding vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Common Stock Shares Outstanding account and Total Liab. At this time, the significance of the direction appears to have strong relationship.
The correlation between Arrowhead Pharmaceuticals' Common Stock Shares Outstanding and Total Liab is 0.75. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Liab in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Common Stock Shares Outstanding and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Arrowhead Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Common Stock Shares Outstanding i.e., Arrowhead Pharmaceuticals' Common Stock Shares Outstanding and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.75 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 06/15/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 79.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.2M | 228.2M | 262.5M | 275.6M | Total Revenue | 243.2M | 240.7M | 276.8M | 290.7M |
Arrowhead Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Arrowhead Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arrowhead Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Other Current Liab | 13.5M | 23.8M | (5.6M) | (46.4M) | (53.4M) | (50.7M) | |
Total Current Liabilities | 40.7M | 146.5M | 74.1M | 866K | 995.9K | 946.1K | |
Total Stockholder Equity | 461.8M | 408.8M | 106.0M | 271.3M | 312.0M | 327.6M | |
Property Plant And Equipment Net | 47.0M | 66.0M | 168.6M | 335.6M | 385.9M | 405.2M | |
Net Debt | (122.4M) | (158.9M) | (26.4M) | 4.3M | 3.9M | 4.0M | |
Retained Earnings | (503.8M) | (644.7M) | (820.8M) | (1.0B) | (923.4M) | (877.3M) | |
Accounts Payable | 6.8M | 9.5M | 2.9M | 35.9M | 41.2M | 43.3M | |
Cash | 143.6M | 184.4M | 108.0M | 110.9M | 127.5M | 133.9M | |
Non Current Assets Total | 200.1M | 325.6M | 315.5M | 654.7M | 752.9M | 790.5M | |
Non Currrent Assets Other | 265.4K | 272K | 29.1M | 361.9M | 416.2M | 437.0M | |
Cash And Short Term Investments | 315.5M | 367.8M | 376.4M | 110.9M | 127.5M | 83.7M | |
Net Receivables | 327.4K | 661.4K | 845.7K | 10.3M | 1.4M | 0.0 | |
Common Stock Total Equity | 187.9K | 194.7K | 197K | 198K | 227.7K | 239.1K | |
Common Stock Shares Outstanding | 100.7M | 103.7M | 105.4M | 106.8M | 122.8M | 128.9M | |
Liabilities And Stockholders Equity | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Inventory | 3.3M | 4.3M | 4.4M | (21.6M) | (19.5M) | (18.5M) | |
Other Current Assets | 1.8M | 2.2M | 20.2M | 7.1M | 8.1M | 8.6M | |
Other Stockholder Equity | 965.4M | 1.1B | 820.9M | 1.3B | 1.5B | 1.6B | |
Total Liab | 60.7M | 301.3M | 586.0M | 478.4M | 550.1M | 577.7M | |
Property Plant And Equipment Gross | 47.0M | 88.9M | 110.3M | 377.5M | 434.1M | 455.8M | |
Total Current Assets | 322.4M | 384.6M | 376.4M | 110.9M | 127.5M | 85.9M | |
Accumulated Other Comprehensive Income | 18.4K | (69K) | (136K) | (3.2M) | (2.9M) | (2.8M) | |
Short Term Debt | 1.1M | 2.3M | 2.8M | 10.6M | 12.1M | 12.8M | |
Common Stock | 194.7K | 197K | 106.0M | 200K | 230K | 218.5K | |
Current Deferred Revenue | 19.3M | 111.1M | 74.1M | 866K | 995.9K | 946.1K | |
Non Current Liabilities Total | 20.0M | 154.8M | 511.9M | 477.5M | 549.2M | 576.6M | |
Property Plant Equipment | 30.9M | 48.7M | 110.3M | 335.6M | 385.9M | 405.2M | |
Other Assets | 68.9M | 96.8M | 218K | 210K | 241.5K | 229.4K | |
Short Term Investments | 171.9M | 183.4M | 268.4M | 292.7M | 336.6M | 353.5M | |
Intangible Assets | 15.4M | 13.7M | 12.0M | 10.3M | 11.8M | 10.2M | |
Other Liab | 8.7M | 41.4M | 190.3M | 56.0M | 64.3M | 67.6M | |
Net Tangible Assets | 446.4M | 395.2M | 398.5M | 261.1M | 300.2M | 202.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.